Evolutions in TAVR patient care video series

Stay up to date on the latest evidence to support your
TAVR clinical practice. Learn from the experts as they
discuss key data releases in this series of short videos.

Alert Indications, Safety, and Warnings

Valve durability

Durability matters for the initial valve selection

Drs. Forrest, O'Hair, and Prof. Sondergaard review recent data on predictors of hemodynamic valve deterioration (HVD), eight-year follow-up from the NOTION trial, and two-year follow-up from the Evolut Low Risk trial. Durability and the correlation between residual gradient and HVD is also discussed.

Valve durability five-year meta-analysis

We caught up with Dr. Guilherme F. Attizzani at TCT 2021 to learn more about his meta-analysis that suggests statistically favorable valve durability for self-expanding TAVs versus SAVR and balloon-expandable TAVs.

Valve hemodynamics

Valve hemodynamics: new data in women

Drs. Herrmann, Modine, and Prof. Pibarot discuss differences in flow and gradients between TAVR and SAVR in women with small aortic annuli from EuroPCR. The importance of avoiding patient-prosthesis mismatch is also discussed.

SURTAVI five-year data highlights

Dr. Popma sits down with Dr. Reardon and Prof. Van Mieghem to discuss SURTAVI five-year results at TCT 2021. The group shares their perspectives on how the data could impact treatment decision-making and lifetime management moving forward.

Procedure optimization

TAVR with Evolut in 2021: contemporary techniques resulting in excellent patient outcomes

Drs. Harvey, Tchétché, and Yakubov discuss results from the Optimize PRO study, TVT-R PPI data, and expedited patient discharge.

Additional resources

Stay informed

Follow us:
Twitter: @MDT_StructHeart
LinkedIn: Medtronic Cardiac and Vascular

Receive email updates about Medtronic TAVR.

Education and resources

Find additional feature information, educational resources, and tools.

Evolut TAVR platform